Here's how it works in private equity ophthalmology.
You're a productive surgeon at a private practice. You've been there for a few years, building your patient base, refining your technique, generating real revenue. Then one day the founding partners announce they're selling to a PE firm. You didn't ask for this. You weren't consulted. But PE needs you to stay because you're the revenue engine, so they offer you a deal: half a million dollars in retention equity just for not leaving.
It sounds generous until you read the fine print.
How Retention Equity Actually Works
That $500,000 isn't cash. It's equity in the platform's holding company, typically structured as profits interests in an LLC. You can't sell it, you can't transfer it, and you can't access any value from it until there's a liquidity event, which means the PE firm has to sell the entire platform to another buyer. That could take 3 years or it could take 7, and the median hold period keeps stretching as interest rates make exits harder.
When PE acquires a physician practice, the consideration is typically split approximately 75% cash and 25% rollover equity. The physician is expected to keep skin in the game, but that skin is illiquid, non-transferable, and subject to restrictions that make it functionally worthless until someone else decides to sell. According to Healio and Arnold and Porter's 2024 analysis, this structure is now standard across PE-backed ophthalmology platforms.
The Vesting Trap That Keeps Ophthalmologists Locked In
The vesting schedule is where the trap really lives. The equity vests over 3 to 5 years, and if you leave before it's fully vested, you forfeit whatever hasn't vested yet. Leave under "bad leaver" conditions, which in many agreements includes voluntary resignation for any reason, and you forfeit everything at cost. That means you get back only the original rollover amount with zero share of any appreciation, even if the platform's value doubled while you were the one generating the revenue that made it double.
According to Nixon Peabody's March 2026 analysis, 20 to 50% of rollover equity now vests on the later of a stated date or a change of control transaction. So you might not fully vest until the PE firm sells, and that decision is entirely outside your control. Your financial future is handcuffed to a timeline that belongs to people who've never met your patients and don't know your name.
And when the platform finally does sell, you'd think that's your payday. But physicians are increasingly required to re-roll 50% or more of their equity into the next buyer's platform, which means a new vesting schedule, a new hold period, and another 5 to 7 years of illiquidity. The handcuff doesn't come off when the platform sells. It just transfers to a different owner and the clock starts over from zero.
Why the "Second Bite" Almost Never Works for Ophthalmologists
We want to be real about how badly the "second bite of the apple" actually works for physicians, because PE sells this concept hard and the reality is brutal. A Health Affairs Scholar study found that of 807 PE-acquired practices from 2016 to 2020, 97.8% of exits were secondary buyouts to other PE firms. These weren't strategic sales to operators who would run the practice long-term. They were financial pass-the-baton transactions where each new owner layers on more debt and extracts more fees. And in the capital stack waterfall, physician common equity gets paid last, after debt repayment, preferred returns, sponsor economics, and transaction fees. By the time your equity actually pays out, the top of the stack has already consumed most of the value that your clinical work created.
The largest PE-backed ophthalmology platform in the country, EyeCare Partners, saw its adjusted EBITDA drop approximately 43% in Q1 2023 compared to the prior year. Its debt fell into deep discount classification, indicating extremely high default risk. When the platform holding your equity is struggling to service its own debt, your common equity position at the bottom of the capital stack is worth next to nothing regardless of what the spreadsheet says.
The Gap Between What PE Promises and What PE Delivers
A healthcare consultant who works with PE-acquired physicians said she spends significant time listening to clients express deep regret after their deals close. An attorney specializing in physician contracts documented a case where an employed surgeon on track for partnership saw the practice sold to PE. The founding partners received mid-six figures each. The employed surgeon, the one who was actually doing most of the surgeries, was offered a mid-five figure bonus. Not equity, not a share of the sale, just a bonus and a new employment agreement with a fresh set of restrictions.
That's the gap between what PE promises when they're trying to get you to stay and what PE delivers when it's time to divide the money. The $500,000 wasn't a gift. It was a price tag on your freedom, calculated precisely to be large enough that walking away feels devastating but small enough that PE still captures the vast majority of the value you create. They've done the math on what it costs to keep a productive surgeon from exploring other options.
The question is whether you've done yours.
This article is for general educational purposes and is not investment advice.
Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you are evaluating private healthcare investments and want to understand the mechanics of this market, we are open to thoughtful conversations.
Contact info@verdira.com | 307-381-3734 | verdira.com
